Sanofi
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Belén Garijo López
- Full Time Employees
- 76,493
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 46, avenue de la Grande ArmEe Paris IF France 75017
- IPO Date
- Jul 1, 2002
- CIK
- 0001121404
- Website
- sanofi.com
- Similar Companies
- Business
- Sanofi is a global biopharmaceutical leader involved in the exploration, development, manufacturing, and commercialization of diverse therapeutic solutions across various international markets. The company operates primarily through its focused segments of Pharmaceuticals and Vaccines, undergoing a strategic evolution to center on innovative biopharmaceutical advancements. Within its Pharmaceutical division, Sanofi delivers specialized care products, including advanced treatments for immunology, such as human monoclonal antibodies, and therapies addressing multiple sclerosis, other neurological conditions, inflammatory diseases, rare disorders, oncology, and specific rare blood conditions. The Vaccines segment remains a cornerstone, providing immunizations for diseases like poliomyelitis, pertussis, influenza, meningitis, and other booster and travel-related vaccines, serving populations globally. In a significant strategic realignment, Sanofi has moved to divest a controlling stake in its Consumer Healthcare unit, Opella, to intensify its focus on high-growth biopharma areas and enhance its research and development capabilities. The company generates revenue predominantly through the sale of its innovative pharmaceutical products and vaccines, complemented by income from licensing agreements, collaborations, and strategic partnerships. Its target market includes a broad spectrum of healthcare providers, such as hospitals, clinics, and pharmacies, alongside patients requiring specialized medical care. Recent initiatives highlight Sanofi's commitment to scientific breakthroughs, with substantial investments in research and development, particularly in immunology and oncology. Key developments include the acquisition of Inhibrx in early 2024 to bolster its rare disease pipeline, a collaboration with Orano Med in late 2024 for next-generation radioligand therapies in oncology, and the buyout of Vigil Neuroscience in May 2025. Furthermore, Sanofi Ventures committed additional capital in September 2025 to foster early-stage biotech and digital health innovations. Its robust pipeline currently features 93 clinical-stage projects, with 36 in Phase 3 or under regulatory review as of October 2025. The company also achieved a positive CHMP recommendation in November 2025 for Teizeild (teplizumab) for stage 2 type 1 diabetes in the European Union. Sanofi was established in 1973 and maintains its headquarters in Paris, France.
Company News
Brokerages Set Sanofi (NASDAQ:SNY) Price Target at $49.50
SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
US FDA approves updated COVID vaccines for 2026-27 season
Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity?
Sanofi: Trump's Vaccine Policy Won't Break The Story
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
AimwellBio Secures Patented Behavioral AI Portfolio Backed by Oxford Science and Sanofi Pilot; Inventor Dr. Chris A. Jones Joins Board of Advisors
Sanofi: How I Leveraged This Undervalued Dividend Aristocrat
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (August 2026)
Press Release: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
Sanofi (NASDAQ:SNY) Receives Consensus Recommendation of “Hold” from Analysts
Sanofi Beats on Q2 Earnings & Sales, Stock Down on Pipeline Setbacks
Sanofi Q2 Earnings Call Highlights
Sanofi Raises Guidance as New CEO Looks to Revamp Drug Pipeline
Sanofi raises sales outlook on Dupixent strength in boost for new CEO
Bank of New York Mellon Corp Grows Holdings in Sanofi $SNY
The Smartest Dividend Stock to Buy With $1,000 Right Now (Spoiler: It Yields 5.6%.)
Cetera Investment Advisers Buys 43,135 Shares of Sanofi $SNY
Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO
Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews